(Q36726212)

English

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors

scientific article published on December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

author name string

Manik Amin

1

1 reference

Europe PubMed Central

15 August 2017

Susan E Minton

2

1 reference

Europe PubMed Central

15 August 2017

Patricia M LoRusso

3

1 reference

Europe PubMed Central

15 August 2017

Smitha S Krishnamurthi

4

1 reference

Europe PubMed Central

15 August 2017

Cheryl A Pickett

5

1 reference

Europe PubMed Central

15 August 2017

Jared Lunceford

6

1 reference

Europe PubMed Central

15 August 2017

Darcy Hille

7

1 reference

Europe PubMed Central

15 August 2017

David Mauro

8

1 reference

Europe PubMed Central

15 August 2017

Mark N Stein

9

1 reference

Europe PubMed Central

15 August 2017

Andrea Wang-Gillam

10

1 reference

Europe PubMed Central

15 August 2017

Lauren Trull

11

1 reference

Europe PubMed Central

15 August 2017

A Craig Lockhart

12

1 reference

Europe PubMed Central

15 August 2017

publication date

1 December 2015

1 reference

Europe PubMed Central

15 August 2017

Investigational New Drugs

1 reference

Europe PubMed Central

15 August 2017

34

1 reference

Europe PubMed Central

15 August 2017

84-95

1 reference

Europe PubMed Central

15 August 2017

1

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1007/s10637-015-0306-7

0 references

Basal aurora kinase B activity is sufficient for histone H3 phosphorylation in prophase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Novel targets in esophageal and gastric cancer: beyond antiangiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora kinase inhibitors synergize with paclitaxel to induce apoptosis in ovarian cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora kinase inhibitors: identification and preclinical validation of their biomarkers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora kinases as targets for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Docetaxel administration schedule: from fever to tears? A review of randomised studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora-A - a guardian of poles

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

The Aurora kinases: role in cell transformation and tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Molecular and biologic basis of upper gastrointestinal malignancy. Gastric carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

30 September 2017

Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

5 September 2018

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

5 September 2018

Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

5 September 2018

Development and biological evaluation of a novel aurora A kinase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4806784

5 September 2018

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-015-0306-7

21 January 2018

Identifiers

10.1007/S10637-015-0306-7

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36726212&oldid=1650488829"